Antisense technology: an overview and prospectus

ST Crooke, BF Baker, RM Crooke… - Nature reviews Drug …, 2021 - nature.com
Antisense technology is now beginning to deliver on its promise to treat diseases by targeting
RNA. Nine single-stranded antisense oligonucleotide (ASO) drugs representing four …

Antisense oligonucleotides targeting apolipoprotein (a) in people with raised lipoprotein (a): two randomised, double-blind, placebo-controlled, dose-ranging trials

…, SG Hughes, MJ Graham, RM Crooke, ST Crooke… - The Lancet, 2016 - thelancet.com
Background Elevated lipoprotein(a) (Lp[a]) is a highly prevalent (around 20% of people)
genetic risk factor for cardiovascular disease and calcific aortic valve stenosis, but no approved …

[PDF][PDF] Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation

…, J Gregory, H Allayee, R Lee, M Graham, R Crooke… - Cell metabolism, 2013 - cell.com
Circulating trimethylamine-N-oxide (TMAO) levels are strongly associated with atherosclerosis.
We now examine genetic, dietary, and hormonal factors regulating TMAO levels. We …

[HTML][HTML] Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides

…, RS Geary, JL Witztum, RM Crooke… - … England Journal of …, 2017 - Mass Medical Soc
Background Epidemiologic and genomewide association studies have linked loss-of-function
variants in ANGPTL3, encoding angiopoietin-like 3, with low levels of plasma lipoproteins. …

[HTML][HTML] Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia

…, NJ Viney, MJ Graham, RM Crooke… - … England Journal of …, 2015 - Mass Medical Soc
Background Apolipoprotein C-III (APOC3) is a key regulator of plasma triglyceride levels.
Elevated triglyceride levels are associated with a risk of adverse cardiovascular events and …

Antisense therapy targeting apolipoprotein (a): a randomised, double-blind, placebo-controlled phase 1 study

…, Q Yang, SM Marcovina, RS Geary, RM Crooke… - The Lancet, 2015 - thelancet.com
Background Lipoprotein(a) (Lp[a]) is a risk factor for cardiovascular disease and calcific aortic
valve stenosis. No effective therapies to lower plasma Lp(a) concentrations exist. We have …

[HTML][HTML] Targeting APOC3 in the familial chylomicronemia syndrome

…, BF Baker, MJ Graham, RM Crooke… - … England Journal of …, 2014 - Mass Medical Soc
<p id="p001">The familial chylomicronemia syndrome is a genetic disorder characterized
by severe hypertriglyceridemia and recurrent pancreatitis due to a deficiency in lipoprotein …

[HTML][HTML] Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

…, BP Monia, ST Crooke, RM Crooke - Journal of lipid …, 2007 - ASBMB
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of a family of proteases
that is thought to promote the degradation of the low density lipoprotein receptor (LDLR) …

Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans

…, BF Baker, J Burkey, ST Crooke, RM Crooke - Circulation …, 2013 - Am Heart Assoc
Rationale: Elevated plasma triglyceride levels have been recognized as a risk factor for the
development of coronary heart disease. Apolipoprotein C-III (apoC-III) represents both an …

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B

…, RZ Yu, E Chuang, MJ Graham, RM Crooke - Circulation, 2006 - Am Heart Assoc
Background— Apolipoprotein B (apoB) is an important structural component of low-density
lipoprotein cholesterol (LDL-C) and plays a key role in LDL-C transport and removal. …